Jamp Pharma Corp Recalls Jamp-Methotrexate (USP 50mg/2mL) Due To Particulate Matter

Jamp Pharma Corporation, in consultation with Health Canada, is voluntarily recalling one lot of Jamp-Methotrexate USP 50mg/2mL due to the potential presence of foreign particulate matter. Methotrexate Injection is administered by health care professionals but Health Canada is also aware that this product may be self-administered by subcutaneous injection (under the skin) by patients at home. The risks associated with subcutaneous injection of foreign particulate matter include local reaction at the injection site and/or swelling or possible allergic reaction and infection.

Speak to your healthcare practitioner if you have concerns about your health. Consult with your healthcare practitioner about stopping the use of this product and getting a replacement medication in order to complete your scheduled therapy. Report any adverse events to Health Canada .